{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=57&state=Texas",
    "query": {
      "state": "Texas",
      "city": "Houston",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 22526,
    "total_pages": 2253,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=58&state=Texas&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Houston&page=56&state=Texas&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T01:13:01.859Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04485260",
      "title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "KRT-232",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kartos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 36,
      "start_date": "2021-01-28",
      "completion_date": "2024-10",
      "has_results": false,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Baltimore, Maryland • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04485260"
    },
    {
      "nct_id": "NCT00827320",
      "title": "Bioequivalency Study of Levetiracetam 1g Tablets Under Fed Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Levetiracetam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roxane Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 26,
      "start_date": "2007-06",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00827320"
    },
    {
      "nct_id": "NCT00355082",
      "title": "Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy, Partial"
      ],
      "interventions": [
        {
          "name": "lamotrigine, 300 mg/day",
          "type": "DRUG"
        },
        {
          "name": "lamotrigine, 250 mg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 226,
      "start_date": "2006-05",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2017-01-02",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 67,
      "location_summary": "Alabaster, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 56 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00355082"
    },
    {
      "nct_id": "NCT03070223",
      "title": "PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Pitavastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 602,
      "start_date": "2017-03-14",
      "completion_date": "2023-08-21",
      "has_results": true,
      "last_update_posted_date": "2024-10-28",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03070223"
    },
    {
      "nct_id": "NCT02186223",
      "title": "The Angel® Catheter Pivotal Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pulmonary Embolism",
        "Deep Vein Thrombosis",
        "Venous Thromboembolism",
        "Trauma"
      ],
      "interventions": [
        {
          "name": "The Angel® Catheter",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "BiO2 Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 172,
      "start_date": "2015-01",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • San Diego, California • Loveland, Colorado + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Loveland",
          "state": "Colorado"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02186223"
    },
    {
      "nct_id": "NCT05814627",
      "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib Matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 487,
      "start_date": "2023-06-15",
      "completion_date": "2026-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 85,
      "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05814627"
    },
    {
      "nct_id": "NCT04677959",
      "title": "A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone propionate/salmeterol (FS)",
          "type": "DRUG"
        },
        {
          "name": "Albuterol",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Asthma Medication",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Rescue Medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 427,
      "start_date": "2021-02-16",
      "completion_date": "2022-03-10",
      "has_results": true,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 46,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04677959"
    },
    {
      "nct_id": "NCT00970996",
      "title": "Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Abraxane",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Interleukin-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interferon alpha 2b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2009-09",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-03",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00970996"
    },
    {
      "nct_id": "NCT05272046",
      "title": "Monopolar and Bipolar Current RFA Knife in POEM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Esophageal Motility Disorders"
      ],
      "interventions": [
        {
          "name": "Per-oral Endoscopic Myotomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Speedboat (Bipolar electrocautery knife)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2022-02-22",
      "completion_date": "2025-10-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05272046"
    },
    {
      "nct_id": "NCT01499303",
      "title": "Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fostamatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2011-12",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-08-22",
      "last_synced_at": "2026-11-16T01:13:01.859Z",
      "location_count": 19,
      "location_summary": "Huntsville, Alabama • Denver, Colorado • New Haven, Connecticut + 16 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01499303"
    }
  ]
}